在未来发展方面，公司黄山技改项目正稳步推进，一期主体已封顶，预计2026年底投产，届时将提升中 药提取和制剂产能。同时，公司产品复产计划（如珍珠明目滴眼液等）和渠道扩张（如全国营销体系搭 建）也在持续进行中。 以上内容基于公开资料整理，不构成投资建议。 经济观察网 基于最新公开信息，天目药业（600671）（600671）近期业绩改善明显，2025年前三季度 实现营业收入1.59亿元，同比增长27.48%，归母净利润1420.88万元，实现扭亏为盈。截至2026年2月11 日，公司股价报20.59元/股，总市值约25.07亿元，今年以来累计上涨18.95%。 公司项目推进 ...

Investment Rating - The investment rating for the pharmaceutical and biotechnology sector is "Outperform the Market" (maintained) [2] Core Insights - The pharmaceutical sector underperformed the market in Q4 2025, with the overall sector down by 9.3% compared to a slight decline of 0.2% in the CSI 300 index. Notably, the pharmaceutical commercial segment showed a positive performance with a 5.3% increase, while other segments like medical services and biological products experienced significant declines [4][8] - The total net asset value of pharmaceutical funds decreased to 358.4 billion yuan, a 9.0% decline quarter-on-quarter. This marks the first time since 2019 that passive pharmaceutical funds (181.8 billion yuan) surpassed active funds (176.5 billion yuan) [4][14] - The overall pharmaceutical holdings across all funds dropped to 7.97%, a decrease of 1.71 percentage points. Active pharmaceutical funds maintained a high concentration with a holding ratio of 97.45% [23] Summary by Sections 1. Market Review - In Q4 2025, the pharmaceutical and biotechnology sector lagged behind the CSI 300 index, with a decline of 9.3%. The chemical pharmaceuticals segment fell by 9.6%, biological products by 12.4%, and medical devices by 10.6% [8] 2. Pharmaceutical Fund Size - As of Q4 2025, the net asset value of pharmaceutical funds was 358.4 billion yuan, down 9.0% from the previous quarter. Active funds accounted for 176.5 billion yuan, a 14.6% decrease, while passive funds reached 181.8 billion yuan, down 2.8% [14] 3. Pharmaceutical Holdings Ratio - The pharmaceutical holdings ratio for all funds was 7.97%, down 1.71 percentage points. Active pharmaceutical funds had a holding ratio of 97.08%, while passive funds had 97.83% [23] 4. Holdings Structure Analysis - The highest sub-sector holding in Q4 2025 was chemical preparations at 37.5%, followed by other biological products at 20.8%. The largest increases in holdings were seen in traditional Chinese medicine (+0.98 percentage points) and chemical preparations (+0.62 percentage points) [29] 5. Additions and Reductions in Holdings - The top three pharmaceutical stocks by the number of funds holding them were Heng Rui Medicine (498 funds), WuXi AppTec (408 funds), and Mindray Medical (204 funds). Notably, Heng Rui Medicine saw a reduction of 236 funds, while Ying En Biological-B experienced an increase of 47 funds [84][88]

"将'炒至表面微黄''嗅到固有香气逸出'等经验性描述，尝试通过标准色卡比对颜色，用电子鼻、电子舌捕捉 气味和味道的特征信号，把'感觉'变成可测量、可重复的参数或范围。"汪坤介绍，用现代技术为传统技 艺"画像"和"建档"，系统性地用影像、数据记录下老药工的关键操作过程和判断节点，建立数字化经验库， 实现传统技艺的"标准传承"。 赵旭还带领团队挖掘古文献和地方特色，将小米煮天麻炮制技术等传统技艺，结合现代技术开展科学研究， 让这些技艺更标准、更高效；探索建立"挖掘—科研—转化—应用"机制，开发特色制剂保光清凉散，将秘方 转化为安全、有效、质量可控的标准化制剂。 "你看我用指尖在厚朴上轻划一下，通过看划痕可以初步判断它的油性。"2月11日，在河南省中医院全国老药 工传承工作室，全国老药工传承工作室建设项目专家、河南省中医院副院长赵旭正在给学生讲解如何鉴定厚 朴的品质。 这道简单划痕，其实凝聚了赵旭摸索近40年的药材鉴别"语言"。他总结出一套完整的药材鉴别方法：观、 触、嗅、尝、悟，看颜色、摸质地、闻气味、尝味道，最后把所有这些感官信息在心里合一起，综合判断一 味药的真伪优劣。 "药是治病救人的，一丝马虎都不能有。要 ...

■ 华润江中药业股份有限公司关于第二期限制性股票激励计划预留授予结果公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 根据中国证券监督管理委员会《上市公司股权激励管理办法》、上海证券交易所、中国证券登记结算有 限责任公司上海分公司的有关规定，华润江中药业股份有限公司（以下简称"公司"）已完成公司第二期 限制性股票激励计划（以下简称"本激励计划"）的预留授予登记工作，有关具体情况如下： 一、本激励计划预留授予情况 公司于2026年2月3日召开第十届董事会第十二次会议，审议通过了《关于向公司第二期限制性股票激励 计划激励对象授予预留限制性股票的议案》，确定本激励计划的预留授予日为2026年2月3日，向符合条 件的28名激励对象授予66万股限制性股票，授予价格为13.70元/股。公司薪酬与考核委员会已事前审议 通过该议案并出具了核查意见。 本次申请授予登记的相关情况与经公司2024年年度股东大会审议通过的公司第二期限制性股票激励计划 的方案及经公司第十届董事会第十二次会议审议通过的预留授予情况相符。 综上， ...

Core Viewpoint - The company is committed to promoting its Pianzaihuang product series to a broader consumer base through multi-channel and multi-level market strategies, aiming to make its products accessible to everyday consumers [1] Group 1: Market Strategy - The company is actively expanding its mainstream chain channels and has established strategic partnerships with several leading chain stores, achieving coverage of over 100,000 terminal stores [1] - The company utilizes self-operated online and offline platforms to provide refined services, ensuring effective medication services for consumers [1] Group 2: Product Development - The company is focusing on expanding its "food and medicine homology" functional foods and health products to meet the diverse needs of different consumers [1]

值得一提的是，近日，奇正藏药旗下澳门全资子公司取得澳门特别行政区政府药物监督管理局核准签发 的《中成药注册证明书》，公司经典藏药催汤颗粒完成澳门注册。此次获批类别为非处方中成药 （OTC），意味着该药品可通过澳门零售药店等渠道直接触达消费者，快速适配当地民生健康需求。 公告显示，催汤颗粒处方系藏族验方，始载于公元15世纪著名藏医药学家宿喀·娘尼多吉所著的《医学 千万舍利》，为呼吸系统领域感冒类用药。 转自：中国证券报·中证网 中证报中证网讯（记者 吴科任）2月13日晚，奇正藏药发布的2025年度业绩快报显示，报告期内，公司 实现营业总收入24.16亿元，同比增长3.34%；归母净利润为6.46亿元，同比增长10.98%；扣非净利润为 4.77亿元，同比增长12.03%。 奇正藏药主营业务为藏药的研发、生产及销售，包括外用止痛药物和口服藏成药、中药等。公司表示， 2025年扣非净利润的增长主要源于营业总收入的增长。 ...

Core Insights - The company focuses on the core goal of "Digital Taiji" and is advancing the integration of four key areas: business digitization, data interoperability, process intelligence, and ecological platformization [2] Group 1: Digital Transformation Initiatives - The company is implementing a comprehensive digital upgrade across marketing, production, and research sectors [2] - Data governance and AI development have achieved core data integration and visualization platform optimization [2] - Innovative applications such as AI agents have been successfully implemented [2] Group 2: Industry Impact - The modern Chinese medicine industry is being transformed into a smart and standardized model driven by data [2] - The company is leading the digitalization of the entire industry chain [2]

证券日报网讯2月13日，天士力（600535）在互动平台回答投资者提问时表示，公司目前经营一切正 常，未来公司将持续加强研发工作以及销售工作，努力提升公司实际价值。 ...

证券日报网讯 2月13日，桂林三金在互动平台回答投资者提问时表示，截至2026年2月10日股东总户数 为19068户。 （文章来源：证券日报） ...

Core Viewpoint - Qizheng Tibetan Medicine (002287.SZ) reported its 2025 annual performance, showing a total operating revenue of 2.416 billion yuan, an increase of 3.34% compared to the same period last year, and a net profit attributable to shareholders of the listed company of 646 million yuan, representing a year-on-year growth of 10.98% [1] Financial Performance - The company achieved total operating revenue of 2.416 billion yuan [1] - The year-on-year growth in total operating revenue was 3.34% [1] - The net profit attributable to shareholders reached 646 million yuan [1] - The net profit saw a year-on-year increase of 10.98% [1]